Annual CFO
-$43.29 M
+$46.08 M+51.56%
31 December 2023
Summary:
Standard BioTools annual cash flow from operations is currently -$43.29 million, with the most recent change of +$46.08 million (+51.56%) on 31 December 2023. During the last 3 years, it has fallen by -$27.87 million (-180.77%). LAB annual CFO is now -2620.74% below its all-time high of -$1.59 million, reached on 01 December 2013.LAB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.87 M
+$11.18 M+28.63%
30 September 2024
Summary:
Standard BioTools quarterly cash flow from operations is currently -$27.87 million, with the most recent change of +$11.18 million (+28.63%) on 30 September 2024. Over the past year, it has dropped by -$16.46 million (-144.21%). LAB quarterly CFO is now -960.69% below its all-time high of $3.24 million, reached on 01 December 2013.LAB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$143.46 M
-$16.46 M-12.96%
30 September 2024
Summary:
Standard BioTools TTM cash flow from operations is currently -$143.46 million, with the most recent change of -$16.46 million (-12.96%) on 30 September 2024. Over the past year, it has dropped by -$95.05 million (-196.35%). LAB TTM CFO is now -8916.72% below its all-time high of -$1.59 million, reached on 01 December 2013.LAB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LAB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.6% | -144.2% | -196.3% |
| 3 y3 years | -180.8% | -193.5% | -251.7% |
| 5 y5 years | -71.8% | -405.0% | -307.4% |
LAB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -180.8% | +51.6% | -298.0% | +55.4% | -251.7% | at low |
| 5 y | 5 years | -180.8% | +51.6% | -898.9% | +55.4% | -830.5% | at low |
| alltime | all time | -2620.7% | +51.6% | -960.7% | +55.4% | -8916.7% | at low |
Standard BioTools Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.87 M(-28.6%) | -$143.46 M(+13.0%) |
| June 2024 | - | -$39.05 M(-37.5%) | -$127.00 M(+30.6%) |
| Mar 2024 | - | -$62.48 M(+344.3%) | -$97.28 M(+124.7%) |
| Dec 2023 | -$43.29 M(-51.6%) | -$14.06 M(+23.2%) | -$43.29 M(-10.6%) |
| Sept 2023 | - | -$11.41 M(+22.3%) | -$48.41 M(-21.4%) |
| June 2023 | - | -$9.33 M(+9.9%) | -$61.61 M(-25.1%) |
| Mar 2023 | - | -$8.48 M(-55.8%) | -$82.27 M(-8.0%) |
| Dec 2022 | -$89.37 M(+102.8%) | -$19.18 M(-22.1%) | -$89.37 M(+15.8%) |
| Sept 2022 | - | -$24.61 M(-17.9%) | -$77.19 M(+24.4%) |
| June 2022 | - | -$29.99 M(+92.4%) | -$62.07 M(+32.8%) |
| Mar 2022 | - | -$15.59 M(+122.7%) | -$46.75 M(+6.1%) |
| Dec 2021 | -$44.06 M(+185.8%) | -$7.00 M(-26.2%) | -$44.06 M(+8.0%) |
| Sept 2021 | - | -$9.49 M(-35.3%) | -$40.79 M(+13.6%) |
| June 2021 | - | -$14.66 M(+13.7%) | -$35.90 M(+49.4%) |
| Mar 2021 | - | -$12.90 M(+245.6%) | -$24.02 M(+55.8%) |
| Dec 2020 | -$15.42 M(-56.2%) | - | - |
| Dec 2020 | - | -$3.73 M(-18.8%) | -$15.42 M(-10.4%) |
| Sept 2020 | - | -$4.60 M(+64.8%) | -$17.20 M(+0.3%) |
| June 2020 | - | -$2.79 M(-35.0%) | -$17.15 M(-11.5%) |
| Mar 2020 | - | -$4.29 M(-22.2%) | -$19.38 M(-45.0%) |
| Dec 2019 | -$35.21 M(+39.7%) | - | - |
| Dec 2019 | - | -$5.52 M(+21.4%) | -$35.21 M(+16.1%) |
| Sept 2019 | - | -$4.55 M(-9.3%) | -$30.33 M(+1.6%) |
| June 2019 | - | -$5.01 M(-75.1%) | -$29.84 M(+2.4%) |
| Mar 2019 | - | -$20.13 M(+3055.2%) | -$29.16 M(+15.7%) |
| Dec 2018 | -$25.20 M(+4.6%) | -$638.00 K(-84.3%) | -$25.20 M(+5.4%) |
| Sept 2018 | - | -$4.06 M(-6.0%) | -$23.90 M(-14.1%) |
| June 2018 | - | -$4.32 M(-73.3%) | -$27.82 M(-12.5%) |
| Mar 2018 | - | -$16.18 M(-2547.2%) | -$31.79 M(+31.9%) |
| Dec 2017 | -$24.10 M | $661.00 K(-108.3%) | -$24.10 M(-32.1%) |
| Sept 2017 | - | -$7.98 M(-3.7%) | -$35.49 M(-13.0%) |
| June 2017 | - | -$8.29 M(-2.3%) | -$40.77 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$8.49 M(-20.9%) | -$39.83 M(+1.8%) |
| Dec 2016 | -$39.14 M(+12.7%) | -$10.73 M(-19.1%) | -$39.14 M(+19.3%) |
| Sept 2016 | - | -$13.26 M(+80.3%) | -$32.81 M(+1.7%) |
| June 2016 | - | -$7.35 M(-5.6%) | -$32.25 M(-1.5%) |
| Mar 2016 | - | -$7.79 M(+76.9%) | -$32.73 M(-5.8%) |
| Dec 2015 | -$34.73 M(+53.5%) | -$4.40 M(-65.3%) | -$34.73 M(+2.6%) |
| Sept 2015 | - | -$12.70 M(+62.2%) | -$33.85 M(+12.8%) |
| June 2015 | - | -$7.83 M(-20.1%) | -$30.02 M(+37.2%) |
| Mar 2015 | - | -$9.80 M(+178.0%) | -$21.88 M(-3.3%) |
| Dec 2014 | -$22.62 M(+1321.9%) | -$3.52 M(-60.2%) | -$22.62 M(+42.6%) |
| Sept 2014 | - | -$8.86 M(-2940.7%) | -$15.86 M(+91.0%) |
| June 2014 | - | $312.00 K(-103.0%) | -$8.30 M(-26.2%) |
| Mar 2014 | - | -$10.55 M(-425.7%) | -$11.25 M(+607.4%) |
| Dec 2013 | -$1.59 M(-90.9%) | $3.24 M(-347.6%) | -$1.59 M(-80.9%) |
| Sept 2013 | - | -$1.31 M(-50.4%) | -$8.33 M(-19.6%) |
| June 2013 | - | -$2.64 M(+198.3%) | -$10.36 M(-11.6%) |
| Mar 2013 | - | -$884.00 K(-74.7%) | -$11.72 M(-32.9%) |
| Dec 2012 | -$17.48 M(-0.4%) | -$3.50 M(+4.9%) | -$17.48 M(+7.7%) |
| Sept 2012 | - | -$3.34 M(-16.6%) | -$16.23 M(+6.3%) |
| June 2012 | - | -$4.00 M(-39.8%) | -$15.28 M(-33.5%) |
| Mar 2012 | - | -$6.64 M(+194.6%) | -$22.96 M(+30.9%) |
| Dec 2011 | -$17.54 M(+52.4%) | -$2.25 M(-5.2%) | -$17.54 M(-0.0%) |
| Sept 2011 | - | -$2.38 M(-79.6%) | -$17.55 M(-4.6%) |
| June 2011 | - | -$11.68 M(+850.3%) | -$18.39 M(+87.9%) |
| Mar 2011 | - | -$1.23 M(-45.6%) | -$9.78 M(-15.0%) |
| Dec 2010 | -$11.51 M(-41.0%) | -$2.26 M(-29.8%) | -$11.51 M(+24.5%) |
| Sept 2010 | - | -$3.22 M(+4.7%) | -$9.25 M(+53.4%) |
| June 2010 | - | -$3.07 M(+4.1%) | -$6.03 M(+104.1%) |
| Mar 2010 | - | -$2.95 M | -$2.95 M |
| Dec 2009 | -$19.51 M(-32.1%) | - | - |
| Dec 2008 | -$28.72 M(+32.0%) | - | - |
| Dec 2007 | -$21.76 M(-2.5%) | - | - |
| Dec 2006 | -$22.31 M | - | - |
FAQ
- What is Standard BioTools annual cash flow from operations?
- What is the all time high annual CFO for Standard BioTools?
- What is Standard BioTools annual CFO year-on-year change?
- What is Standard BioTools quarterly cash flow from operations?
- What is the all time high quarterly CFO for Standard BioTools?
- What is Standard BioTools quarterly CFO year-on-year change?
- What is Standard BioTools TTM cash flow from operations?
- What is the all time high TTM CFO for Standard BioTools?
- What is Standard BioTools TTM CFO year-on-year change?
What is Standard BioTools annual cash flow from operations?
The current annual CFO of LAB is -$43.29 M
What is the all time high annual CFO for Standard BioTools?
Standard BioTools all-time high annual cash flow from operations is -$1.59 M
What is Standard BioTools annual CFO year-on-year change?
Over the past year, LAB annual cash flow from operations has changed by +$46.08 M (+51.56%)
What is Standard BioTools quarterly cash flow from operations?
The current quarterly CFO of LAB is -$27.87 M
What is the all time high quarterly CFO for Standard BioTools?
Standard BioTools all-time high quarterly cash flow from operations is $3.24 M
What is Standard BioTools quarterly CFO year-on-year change?
Over the past year, LAB quarterly cash flow from operations has changed by -$16.46 M (-144.21%)
What is Standard BioTools TTM cash flow from operations?
The current TTM CFO of LAB is -$143.46 M
What is the all time high TTM CFO for Standard BioTools?
Standard BioTools all-time high TTM cash flow from operations is -$1.59 M
What is Standard BioTools TTM CFO year-on-year change?
Over the past year, LAB TTM cash flow from operations has changed by -$95.05 M (-196.35%)